BDTX Stock Overview
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Black Diamond Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.06 |
| 52 Week High | US$6.85 |
| 52 Week Low | US$1.43 |
| Beta | 2.64 |
| 1 Month Change | -2.50% |
| 3 Month Change | 77.54% |
| 1 Year Change | 244.22% |
| 3 Year Change | -81.81% |
| 5 Year Change | n/a |
| Change since IPO | -87.18% |
Recent News & Updates
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31
Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Recent updates
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11Black Diamond Therapeutics EPS misses by $0.16
May 07We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Feb 26What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition
Jan 05Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?
Dec 01
Black Diamond nominates development candidate for glioblastoma program
Nov 20Black Diamond Therapeutics EPS beats by $0.02
Nov 10Black Diamond Therapeutics: One To Watch In Precision Oncology Space
Oct 23Shareholder Returns
| BDTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.2% | 1.5% | 1.2% |
| 1Y | 244.2% | 1.1% | 24.7% |
Return vs Industry: BDTX exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: BDTX exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| BDTX volatility | |
|---|---|
| BDTX Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BDTX's share price has been volatile over the past 3 months.
Volatility Over Time: BDTX's weekly volatility has decreased from 36% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 54 | Mark Velleca | www.blackdiamondtherapeutics.com |
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial.
Black Diamond Therapeutics, Inc. Fundamentals Summary
| BDTX fundamental statistics | |
|---|---|
| Market cap | US$263.18m |
| Earnings (TTM) | -US$82.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs BDTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$82.44m |
| Earnings | -US$82.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BDTX perform over the long term?
See historical performance and comparison